RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

I agree that the general view of the RD indication potential expressed on this thread is an underestimate. But the question yet-to-be-answered is: Will a potential partner offer an upfront that reflects chronic use potential before there is any chronic use data at all? I expect that the most likely initial offers will include a second major (maybe bigger) milestone payment upon successful completion of a chronic use Phase IIa, that way the BP isn't taking the risk in advamce. However, as you accurately note, there are a number of pain companies who could bid against each other for this technology, and that raises the likelihood that one of them would 'break from the pack' and offer a larger upfront payment, instead of relying upon a contingent milestone.

NeuroInvestment